Biomarker ID | 322 |
PMID | 18553995 |
Year | 2008 |
Biomarker | Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated (Mean Ratio: 0.49 ±0.08) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- FLT4 human kinase ARCHS4 coexpression,BMX human kinase ARCHS4 coexpression, FLT1 human kinase ARCHS4 coexpression,ACVRL1 human kinase ARCHS4 coexpression, ABL2 human kinase ARCHS4 coexpression |
Experiment | Prostate cancer Vs Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 20 patients were chosen for the study. 10 patients with Prostate Cancer and 10 patients with benign prostatic hyperplasia (BPH). |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p≤0.01 |
Method Used | Isobaric tag for relative and absolute quantitation (iTRAQ) , two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) |
Clinical | No |
Remarks | Mean ratio corresponds to the protein reporter ion intensity originating from PCa relative to BPH. Immunohistochemistry was performed on selected genes- PSMA, AMACR, and MUC18 to confirm iTRAQ results |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | MCAM |